Follow
V Craig Jordan
V Craig Jordan
University of Texas MD Anderson Cancer Center
Verified email at mdanderson.org - Homepage
Title
Cited by
Cited by
Year
The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial
SR Cummings, S Eckert, KA Krueger, D Grady, TJ Powles, JA Cauley, ...
Jama 281 (23), 2189-2197, 1999
25561999
Tamoxifen: a most unlikely pioneering medicine
VC Jordan
Nature reviews Drug discovery 2 (3), 205-213, 2003
25192003
Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial
VG Vogel, JP Costantino, DL Wickerham, WM Cronin, RS Cecchini, ...
Jama 295 (23), 2727-2741, 2006
20912006
Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer
RR Love, RB Mazess, HS Barden, S Epstein, PA Newcomb, VC Jordan, ...
New England journal of medicine 326 (13), 852-856, 1992
14561992
The pharmacology and clinical uses of tamoxifen
BJA Furr, VC Jordan
Pharmacology & therapeutics 25 (2), 127-205, 1984
11561984
Basic guide to the mechanisms of antiestrogen action
JI Macgregor, VC Jordan
Pharmacological reviews 50 (2), 151-196, 1998
10281998
Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial
JA Cauley, L Norton, ME Lippman, S Eckert, KA Krueger, DW Purdie, ...
Breast cancer research and treatment 65, 125-134, 2001
9632001
International union of pharmacology. LXIV. Estrogen receptors
K Dahlman-Wright, V Cavailles, SA Fuqua, VC Jordan, ...
Pharmacological reviews 58 (4), 773-781, 2006
8232006
Update of the national surgical adjuvant breast and bowel project study of tamoxifen and raloxifene (STAR) P-2 trial: preventing breast cancer
VG Vogel, JP Costantino, DL Wickerham, WM Cronin, RS Cecchini, ...
Cancer prevention research 3 (6), 696-706, 2010
7462010
MCF-7: the first hormone-responsive breast cancer cell line
AS Levenson, VC Jordan
Cancer research 57, 3071-3078, 1997
6741997
A monohydroxylated metabolite of tamoxifen with potent antioestrogenic activity
VC Jordan, MM COLLINS, L ROWSBY, G Prestwich
Journal of Endocrinology 75 (2), 305-316, 1977
6401977
The estrogen receptor: a model for molecular medicine
EV Jensen, VC Jordan
Clinical cancer research 9 (6), 1980-1989, 2003
6192003
Development of antiestrogens and their use in breast cancer: eighth Cain memorial award lecture
LJ Lerner, VC Jordan
Cancer research 50 (14), 4177-4189, 1990
6001990
Biochemical pharmacology of antiestrogen action.
VC Jordan
Pharmacological Reviews 36 (4), 245-276, 1984
5841984
Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse
MM Gottardis, SP Robinson, PG Satyaswaroop, VC Jordan
Cancer research 48 (4), 812-815, 1988
5681988
Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration
MM Gottardis, VC Jordan
Cancer Research 48 (18), 5183-5187, 1988
5461988
Endocrine pharmacology of antiestrogens as antitumor agents
VC Jordan, CS Murphy
Endocrine reviews 11 (4), 578-610, 1990
5241990
Effect of tamoxifen (ICI 46,474) on initiation and growth of DMBA-induced rat mammary carcinomata
VC Jordan
European Journal of Cancer (1965) 12 (6), 419-424, 1976
5211976
Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 2. Clinical considerations and new agents
VC Jordan
Journal of medicinal chemistry 46 (7), 1081-1111, 2003
5072003
Most plastic products release estrogenic chemicals: a potential health problem that can be solved
CZ Yang, SI Yaniger, VC Jordan, DJ Klein, GD Bittner
Environmental health perspectives 119 (7), 989-996, 2011
4972011
The system can't perform the operation now. Try again later.
Articles 1–20